KRAS

News

Hutchmed rises on $1.3bn KRAS licensing deal with GSK

GSK has paid Hutchmed $110m upfront for rights to a preclinical KRAS and EGFR-directed drug with potential in colorectal, pancreatic, and lung cancer.

News

NICE aims to cut funding for Amgen lung cancer drug Lumykras

Amgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.

News

Roche's KRAS drug tops its rivals in lung cancer trial

Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib.

News

Firefly in a jar illustration on black background

J&J lights up $1bn offer for pan-KRAS developer Firefly

Johnson & Johnson has built its presence in KRAS drugs for cancer with a $1bn deal to buy Firefly Bio and its degrader-antibody conjugate platform.

News

Pedestrian crossing green and red lights

MSD said to have pulled back from Revolution Meds deal

Negotiations between MSD and Revolution Medicines over a possible $30bn takeover of Revolution Medicines have reportedly collapsed.

News

Spinning top in black and white, revolving

Report says MSD is in talks to buy Revolution Meds

MSD is rumoured to be in talks to buy Revolution Medicines and its KRAS inhibitor pipeline in a deal that could be worth up to $32 billion.

Hutchmed rises on $1.3bn KRAS licensing deal with GSK

NICE aims to cut funding for Amgen lung cancer drug Lumykras

Roche's KRAS drug tops its rivals in lung cancer trial

J&J lights up $1bn offer for pan-KRAS developer Firefly

MSD said to have pulled back from Revolution Meds deal

Report says MSD is in talks to buy Revolution Meds

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

KRAS

Editor's Picks